1Kjekshus J,Pedersen TR,OlssonAG,et al.The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease[J].J Card Fail,1997,3(4):249-254.
2Lewis SJ,Moye LA,Sacks FM,et al.Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range[J].Ann Intern Med,1998,129(9):681-689.
3Ankrast P,Yndestad A,Damas JK,et al.Inflammation and chronic heart failure potential the rapeutic role of intravenous immunoglobulin[J].Autoimmun Rev,2004,3(3):221-227.
5Porter KE,Turner NA,O′Reagn DJ,et al.Simvasatin Reduces Human Atrial Myofibroblast Proliferation Indepently of Cholesterol Lowering Via Inhibition of RhoA[J].Cardiovasc Res,2004,61(4):745-755.
9Sola S,Mir MQ,Rajagopalan S,et al.Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure[J].J Card Fail,2005,11(8):607-612.
8Sola S, Mir MQ, Rajagopalan S, et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail, 2005,11 (8) : 607.
9Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 1999,340(6):448-454.
10Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail,2002,4(3):331-336.
5KAPADIA S, DIBBS Z, KURRELMEYER K, et al. The role of cytokines in the failing human heart[J]. Cardiol Clin, 1998, 16(4) : 645-646.
6Sacks FM, Maupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronaryevents in the Cholesterol and Recurrent Events (CARE) trial [ J]. Circulation,2000,102 (16) : 1886-1892.
7Lee SJ, Campos H, Moye LA, et al. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients [ J ]. Arterioscler Thromb Vasc Biol,2003,23 (5) :853-858.
8Olivieri O, Mattinelli N, Girelli D, et al. Apolipoprotein CIII predicts cardiovas-cular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation [ J ]. J Thromb Haemost, 2010,8(3) :463-471.
9Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small a-apolipoproteins [ J ]. Arterioscler Thromb Vasc Biol, 2010,30 (2) :239-245.
10Dinkel RE, Barrett PH, Demant T, et al. In-vivo metabolism of VLDL-apolipoprotein-B,-C III and -E in normolipidemic subjects [ J ]. Nutr Metab Cardiovasc Dis, 2006,16(3) :215-221.
